地舒单抗与罗莫索单抗在重度骨质疏松患者中的新型序贯治疗方案
本文报道3例长期接受地舒单抗治疗仍发生多次脆性骨折的重度骨质疏松患者,采用新型重叠序贯策略:末次地舒单抗后3个月启动罗莫索单抗,罗莫索单抗开始后6个月因骨转换标志物升高而重新启用地舒单抗。结果显示腰椎骨密度增加约5%–22%,1例全髋骨密度增加8%,无新发椎体骨折。作者认为该方案骨密度改善优于既往标准方案,但需更大样本前瞻性对照研究证实。
要点
- 3例重度骨质疏松患者采用地舒单抗与罗莫索单抗重叠序贯治疗,腰椎骨密度增加约5%–22%。
- 1例患者全髋骨密度在罗莫索单抗治疗12个月后增加8%。
- 治疗期间无新发椎体骨折,重新启用地舒单抗后所有病例骨吸收升高均被抑制。
核心结论
- 地舒单抗与罗莫索单抗的新型重叠序贯治疗使腰椎和髋部骨密度改善大于既往标准方案所报道的改善。
- 需要更大规模的前瞻性对照研究来证实这些发现,并确定对地舒单抗预处理患者使用罗莫索单抗以最大化骨密度增益和最小化骨折风险的最佳用法。
研究设计与样本
- 本文描述3例重度骨质疏松且长期接受地舒单抗治疗仍发生多次脆性骨折的患者,采用新型重叠序贯治疗。
- 罗莫索单抗在末次地舒单抗剂量后3个月开始;罗莫索单抗开始后6个月,因骨转换标志物升高而重新启用地舒单抗,而非等待罗莫索单抗疗程完成。
主要发现
- 患者腰椎骨密度增加约5%–22%,1例患者在罗莫索单抗治疗12个月后全髋骨密度增加8%。
- 血清骨转换标志物显示,尽管与地舒单抗重叠治疗,罗莫索单抗仍产生促骨形成效应。
- 重新启用地舒单抗后,所有病例的骨吸收升高均被抑制。
- 治疗期间无新发椎体骨折发生。
局限性
- 原文指出,在重度骨质疏松患者中,地舒单抗与罗莫索单抗之间的最佳序贯治疗方法尚不明确。
- 原文指出,探索从地舒单抗转换为罗莫索单抗序贯治疗的有限研究仅报告骨密度改善轻微至无改善,且对反弹性骨转换的抑制不充分。
- 原文结论指出,需要更大规模的前瞻性对照研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab is unclear. We utilised a novel overlapping strategy in three patients with very-high fracture risk despite long-term denosumab which led to greater bone density improvements than previously reported with standard approaches. Larger confirmatory prospective studies are needed. PURPOSE/INTRODUCTION: In patients with severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab has not been established. The ideal strategy would maximise gains in bone mineral density (BMD) with romosozumab and effectively mitigate the risk of rebound increased bone turnover when sequencing from denosumab. Limited studies exploring the sequence from denosumab to romosozumab report only modest-to-no improvement in BMD and inadequate suppression of rebound bone turnover. METHODS: We describe three patients with severe osteoporosis and multiple fragility fractures despite long-term denosumab. A novel overlapping sequential treatment approach was utilised to maximise therapeutic benefit given these patients had a very high fracture risk. Romosozumab was commenced 3 months after the last denosumab dose. Instead of waiting until completion of romosozumab, denosumab was recommenced 6 months after commencing romosozumab in response to rising bone turnover markers. RESULTS: Patients experienced a ~ 5-22% increase in lumbar spine BMD, and one patient had an 8% increase in total hip BMD after 12 months romosozumab. Serum bone turnover markers demonstrated an anabolic effect of romosozumab occurred despite overlapping treatment with denosumab. Recommencement of denosumab suppressed an increase in bone resorption in all cases. No new vertebral fractures occurred during this treatment. CONCLUSIONS: A novel overlapping sequential treatment approach between denosumab and romosozumab produced greater improvements in lumbar spine and hip BMD than previously reported with standard approaches. Larger prospective controlled studies are needed to confirm these findings and establish the optimal use of romosozumab in patients pre-treated with denosumab to maximise BMD gains and minimise fracture risk.
引用
- Kumar S, Gild ML, McDonald MM, et al. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporos Int. 2024. PMID: 38839655. doi:10.1007/s00198-024-07139-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。